firefighters, beverage tasters, natural gas, chemicals and industrial substances workers 3, 4 . Olfactory dysfunction is often an early manifestation of other central nervous system neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease 5 and Lewy body dementia, and its assessment may be useful for diagnosis 6 . Olfactory dysfunction in MS has also been reported in the literature 7 . Some studies have shown that it is related to lesions in the olfactory regions in the brain (inferior frontal and temporal lobe) 6 . Studies that investigated the olfactory function in MS patients showed a hyposmia of 15% according to Hawkes and Shepard 8 ; according to Zivadinov et al. 9 it was 22%, and according to Doty's study, 38.5% compared to control groups 10 . The reduction of olfactory function can improve during remission periods and worsen during relapses 6 . The olfactory function in MS patients affects the detection threshold capacity, which is damaged in the early stage of the disease, and the ability to identify smells, which appears to be more correlated with the disease's progression
.
This study aimed to assess the olfactory function in patients diagnosed with MS using the Connecticut Chemosensory Clinical Research Center olfactory test, to determine any correlation between the olfactory alteration, the disease duration, and the Expanded Disability Status Scale (EDSS).
METHOD

Population
This was a controlled cross-sectional study conducted with 100 MS patients (McDonald's criteria) 12 , treated at the Multiple Sclerosis Care and Treatment Center of the School of Medical Sciences of Santa Casa de São Paulo, between January and June 2015. All the patients were recruited during their MS follow-up visits.
The inclusion criteria were the diagnoses of MS and being monitored and treated at the Multiple Sclerosis Care and Treatment Center's clinic.
Exclusion criteria were patients over 60 years of age, complaint of nasal obstruction, nasal allergies and/or rhinorrhea, trauma, nasal surgery, or previous neurosurgery, respiratory tract infections and the use of immunosuppressives.
All the assessed patients underwent a facial CT to exclude any other explanation for the olfactory alteration 13 . Before the olfactory function test, we conducted a test with the Glatzel mirror as an aid to the diagnosis of mechanical nasal obstruction 14 . Besides that, we assessed a control group of 100 non-MS patients, using the same exclusion criteria.
Olfactory test
After collecting data about their disease, and about the presence or absence of an olfactory complaint, the patients took the Connecticut Chemosensory Clinical Research Center olfactory test 15 . Only patients who had regular olfactory function (normosmia) underwent the screening 16 . Those who had olfactory alterations were thoroughly tested.
The Connecticut test is divided into two parts: the first assesses the smell threshold, and the second assesses the identification of smells. In both stages, each nasal cavity is assessed separately during the presentation of smells, closing them one at a time by digital compression, as it is possible to present with unilateral hyposmia/anosmia. During the test, the patient remained blindfolded 15 .
The threshold test uses different concentrations and dilutions of 1-butanol in 11 separate glass flasks, numbered from "0 to 10", in descending order of concentration. The flask "0" corresponds to 1-butanol without dilution, at a concentration of 4%. The other dilutions were in the ratio 1:3. The blindfolded patient was offered the flask of the lowest concentration (n # 10) and a flask with water, to identify which had the strongest smell. If the answer was wrong, the patient took the next highest concentration flask (n # 9), and so on until they were successful. After the first correct response, the same flask was again presented to the patient, as the test is completed only when the patient responded to it correctly four times in a row, thus confirming their smell threshold, represented by the flask number 15 .
In the smell identification phase, seven plastic flasks containing different substances (talc, chocolate, coffee, cinnamon, naphthalene, ethyl alcohol and tobacco) are randomly presented to the patient. The patient had to name the substance after smelling it. Responses like "no smell" or "I don't know" were considered. If the response was wrong, the same substance was presented for the second time, but if there was a correct response, the previous mistake was ignored. The test score was the number of items correctly identified in the first or the second endeavor
.
The patient was finally presented with a flask containing ammonium chloride, to evaluate trigeminal perception. This was important to detect possible simulators, as the trigeminal is generally preserved in the impairment of the olfactory pathway. The total score for each cavity test was expressed by the arithmetic mean of the scores obtained in the smell threshold and smell identification.
Statistical analysis
Analysis of the results was with the statistical program SPSS version 20. The variables were expressed as mean and standard deviation for continuous variables, and recorded as a percentage (categorical variables). All tests were two-caudate. Normality tests were used based on the method of Kolmogorov-Smirnov and Shapiro-Wilk. Categorical variables were analyzed by the chi-squared method and we used the Fisher's exact test correction whenever it was necessary. Continuous variables were assessed by
RESULTS
One hundred MS patients were assessed, 72 women and 28 men, with an EDSS mean of 2, and an average time after diagnosis of 93 months. Olfactory alterations were observed in 32% of the MS patients, while in the control group only 3% had olfactory alteration. Tables 1 and 2 shows each group's characteristics.
The boxplot shows a cutoff of 4 for EDSS (Figure 1) , which approximately coincides with the EDSS mean in patients with olfactory alteration. Therefore, if a patient has an EDSS above 4, they have (odds ratio) 5.2 times the risk of having an olfactory alteration, when compared to a patient with a lower EDSS (p = 0.001), range of confidence (95%): 1.8-15.1.
With a sensitivity of 97% and specificity of 88%, this study showed that when the EDSS value is smaller than 0.5, the patient is unlikely to show olfactory alteration.
We also observed that if an MS patient is older than 38 years, the risk of having an altered test is 2.2 times greater than a younger person (p = 0.01) . We also observed that MS patients without olfactory alteration were within 80.5 months after diagnosis, against 119 months duration after diagnosis in the patients who had olfactory alteration, showing a correlation between olfactory alteration and time since diagnosis (p = 0.031).
DISCUSSION
The frequency of olfactory alteration in MS patients was 32%, which is consistent with other findings in the literature, for example, the studies of Hawkes (15%), Zivadinov (22%) and Doty (32.5%) 8, 9, 10 . The sense of smell is very important to the safety and quality of life. People with olfactory alterations have a significant reduction in food intake because of decreased pleasure, thus becoming even more susceptible to injuries 3, 4 . When analyzing the results, a patient with EDSS above 4 had 5.2 times the increased risk of olfactory alteration, which is consistent with other studies. Caminiti et al. 7 and Silva et al. 6 showed that olfactory dysfunction was correlated with higher EDSS scores, and a longer duration of disease, corroborating previous studies in which the olfactory dysfunction correlates directly to the level of disability 8, 9, 11, 17 . Considering the relationship between the time of diagnosis and olfactory alteration, this study showed that patients with an abnormal test had a longer duration since diagnosis (p = 0.031), an average of 119 months, and that the older the patient, the greater the risk of olfactory alteration, as described by Silva et al 6 . The correlation of olfactory alteration and age demonstrated that MS patients over 38 years old are 2.2 times (p = 0.01) more likely to have olfactory alteration.
In the study by Silva et al. 6 , it was observed that the EDSS mean in all the patients studied was 2.92 ± 2.25 with a mean age of 41.91 ± 11.28 years, while in patients with olfactory alterations the EDSS mean was around 5.26 ±2.22 (p < 0.001), with a mean age of 51,47± 10.03 years. In our study, the studied population's EDSS mean was 2, but it was 4 in patients with alteration, with an age of 38 years. This demonstrates similarity between our population and Silva et al. 6. In conclusion, through the data obtained in this study we observed that MS patients are likely to experience olfactory alteration, so its assessment may be a useful tool to the follow-up care of these patients, although more studies are necessary to evaluate correlations in MS evolution.
